You are here : Home > INDUSTRIAL INNOVATION > DEMOS > Organoid-on-chip

Articles ＆ files | Focus


Organoid-on-chip

Microfluidic devices with cellular systems  that model human physiology and pathologies to facilitate targeted healthcare.


​

Published on 24 September 2026





​​​

​Organoid-on​​-chip​​​​​​​​​

Microfluidic devices with cellular systems that model human physiology and pathologies to facilitate targeted healthcare

​​

Organoids are self-organizing multicellular assemblies created from the proliferation and differentiation of stem cells. 

Microfluidic chips create an environment that encourages their growth and reproduces the spatial and biological constraints to which cells would be exposed in their original tissue. Sensors can also be added to the system. This combination makes it possible to grow a tissue substitute, observe it and eventually communicate with it in real time. This is a revolution for biology research, biopharmaceutical R&D and regenerative medicine. 

CEA-Leti is developing technologies to guide cell self-organization, differentiation and maturation in space and time, as well as the means to characterize and measure the physiological functions of one or more organoids-on-a-chip.


What it can do?​

Areas of research include: 

  • Translational research tools for biology
  • Identifying new therapeutic targets
  • Improving the success rate of clinical trials for innovative therapies
  • Personalized medicine: selecting therapeutic agents tailored to a patient's disease
  • Graft monitoring​

 What makes it unique?​
​

CEA-Leti's organoids-on-a-chip enable precise monitoring by using:

  • Organoid vascularization (in collaboration with CEA-Irig)
  • On-board sensors for real-time monitoring of organoid physiological functions
  • Innovative microfluidic architectures to integrate complex biological protocols
  • Heterogeneous thermoplastic/silicon integration
  • Pre-industrial equipments, rapid prototyping and support for industrialization
​​
​
 
​​
​Scientific publications

​
​​A world first​

In 2022, the CEA was able to sustain for a month islets of Langerhans, which help regulate blood glucose levels by releasing insulin. In addition, individual islet insulin production was quantified to determine which were the most "efficient". A first that may one day improve the efficacy of islet transplants performed on diabetic patients. 

​
Interested in this technology?​

 Contact 

  Fl​yer ​

Enjoy the bilingual option by opening the document with Acrobat Reader​